Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PreveCeutical MedicalPRVCF -4.69% EV-to-EBITDA is -11.86 as of Aug. 08, 2026. The stock has 3 warning signs investors should review. Among 409 Biotechnology companies, PreveCeutical Medical ranks worse than 244498.53% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PreveCeutical Medical's enterprise value is $11.47 Mil.
PreveCeutical Medical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.97 Mil. Therefore, PreveCeutical Medical's EV-to-EBITDA for today is -11.86.
The historical rank and industry rank for PreveCeutical Medical's EV-to-EBITDA or its related term are showing as below:
PRVCF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.67 Med: 0 Max: 0
Current: -11.86
PRVCF's EV-to-EBITDA is ranked worse than 100% of 409
companies
in the Biotechnology industry
Industry Median: 12.99
vs PRVCF: -11.86
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
PreveCeutical Medical (OTCPK:PRVCF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PreveCeutical Medical's PE Ratio (TTM) for today is calculated as:
PreveCeutical Medical's share price for today is $0.01077.
PreveCeutical Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
PreveCeutical Medical EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for PreveCeutical Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRVCF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, PreveCeutical Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PreveCeutical Medical EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PreveCeutical Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PreveCeutical Medical's EV-to-EBITDA falls into.
PreveCeutical Medical's current Enterprise Value is $11.47 Mil.
PreveCeutical Medical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PreveCeutical Medical (PRVCF) has a EV-to-EBITDA of -11.86 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PreveCeutical Medical. According to the industry distribution chart, PreveCeutical Medical ranks #999999 out of 409 companies in the Biotechnology industry.
Is PreveCeutical Medical's EV-to-EBITDA too high?
PreveCeutical Medical's current EV-to-EBITDA is -11.86. Based on the distribution chart, PreveCeutical Medical ranks #999999 out of 409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does PreveCeutical Medical's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PreveCeutical Medical ranks #999999 out of 409 companies for EV-to-EBITDA. This places PreveCeutical Medical in the lower half of its industry. The industry median EV-to-EBITDA is 12.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.99, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PreveCeutical Medical. For the Biotechnology industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PreveCeutical Medical's current EV-to-EBITDA is -11.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PreveCeutical Medical stock overvalued right now?
PreveCeutical Medical (PRVCF) has a current EV-to-EBITDA of -11.86. The current EV-to-EBITDA is -11.86. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PreveCeutical Medical (PRVCF), the current EV-to-EBITDA is -11.86 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PreveCeutical Medical Inc is a health sciences company. The principal business activity of the company is the development of options for preventive and curative therapies utilizing organic and nature-identical products. The company is engaged in licensing, branding, and marketing nutraceutical and wellness products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRVCF has been successfully added to your 
